VGX100 (anti-VEGFC)

    应用:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
功能和特点
  • 宿主种属: 人(Human)
  • 种属反应性: 人(Human)
  • 亚型: Human IgG1
  • 偶联: Unconjugated
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
Ab177881-100μg
100μg 现货 Stock Image
Ab177881-1mg
1mg 现货 Stock Image
Ab177881-5mg
5mg 现货 Stock Image
Ab177881-10mg
10mg 期货 Stock Image

基本信息

产品名称 VGX100 (anti-VEGFC)
英文别名 Flt4 ligand | Flt4-L | Vascular endothelial growth factor-related protein | VEGF-C | VRP
规格或纯度 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属 人(Human)
特异性 VEGFC
种属反应性 人(Human)
偶联 Unconjugated

产品属性

克隆类型 重组抗体
Format Whole IgG
亚型 Human IgG1
轻链亚型 lambda
SDS-PAGE 143.6 kDa
纯化方法 Protein A purified
纯度 >95%
物理外观 Liquid
防腐剂 No
浓度 见COA
储存温度 -80℃储存,避免反复冻融
运输条件 超低温冰袋运输
稳定性与储存 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
分子类型 抗体

图片

VGX100 (anti-VEGFC) (Ab177881) - SEC
The purity of VGX100 (anti-VEGFC) (Ab177881) is more than 95% verified by HPLC.

VGX100 (anti-VEGFC) (Ab177881) - ELISA
Immobilized hVEGFC-his at 2.0 μg/mL can bind VGX100 (anti-VEGFC) (Ab177881) with the EC₅₀ of 4.16 ng/mL.

关联靶点(人)

VEGFC Tbio 血管内皮生长因子C(Vascular endothelial growth factor C) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

安全和危险性(GHS)

质量标准

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到3个结果

批号(Lot Number) 证书类型 日期 货号
ZJ24F0303090 分析证书 24-03-08 Ab177881
ZJ24F0303089 分析证书 24-03-08 Ab177881
ZJ24F0303088 分析证书 24-03-08 Ab177881

参考文献

1. Joukov, V V and 8 more authors..  (1996)  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases..  The EMBO journal,  (1): [PMID:8612600]
2. Joukov, V V and 8 more authors..  (1996)  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases..  The EMBO journal,  (15): [PMID:8617204]
3. Lee, J J and 5 more authors..  (1996)  Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4..  Proceedings of the National Academy of Sciences of the United States of America,  (5): [PMID:8700872]
4. Joukov, V V and 8 more authors..  (1997)  Proteolytic processing regulates receptor specificity and activity of VEGF-C..  The EMBO journal,  (1): [PMID:9233800]
5. Fitz, L J LJ and 17 more authors..  (1997)  Characterization of murine Flt4 ligand/VEGF-C..  Oncogene,  (31): [PMID:9247316]
6. Leppänen, Veli-Matti VM and 9 more authors..  (2010)  Structural determinants of growth factor binding and specificity by VEGF receptor 2..  Proceedings of the National Academy of Sciences of the United States of America,  (9): [PMID:20145116]
7. Gordon, Kristiana K and 12 more authors..  (2013)  Mutation in vascular endothelial growth factor-C, a ligand for vascular endothelial growth factor receptor-3, is associated with autosomal dominant milroy-like primary lymphedema..  Circulation research,  (15): [PMID:23410910]
8. Leppänen, Veli-Matti VM and 10 more authors..  (2013)  Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation..  Proceedings of the National Academy of Sciences of the United States of America,  (6): [PMID:23878260]
9. Balboa-Beltran, Emilia E and 9 more authors..  (2014)  A novel stop mutation in the vascular endothelial growth factor-C gene (VEGFC) results in Milroy-like disease..  Journal of medical genetics,  [PMID:24744435]

溶液计算器